Eosinophilic granulomatosis with polyangiitis
Not recruitingStudy on Benralizumab and Mepolizumab for Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) Receiving Standard Care
Study on Benralizumab and Mepolizumab for Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) Receiving Standard Care
- Disease:Eosinophilic granulomatosis with polyangiitis
- Substances:BenralizumabMepolizumab+3
Belgium- Participants:18–64 years · 65+ years
- Substances:Benralizumab
- Sponsor:AstraZeneca AB












